đánh giá chất lượng cuộc sống theo bảng sf 36 trước và sau điều trị tích cực bệnh nhân suy tim mạn

493

-36


Phạm Văn Cường
1
, Hoàng Anh Tiến, Huỳnh Văn Minh
2
1

2




Mục tiêu:  -


Đối tượng và phương pháp:  


 
SF-36.
Kết quả: Có 

 
  

Kết luận:  


SUMMARY
EVALUATION THE QUALITY OF LIFE BY SF-36 BEFORE AND AFTER
INTENSIVE TREATMENT THE CHRONIC HEART FAILURE
Objectives: This evaluation was performed to assess the effects of an inpatient on the quality
of life related to chronic heart failure patients.
Subject and method: Ninety patients (aged 51±13 years) including 30 heart failure patients
due to valvular heart diseases, 30 due to coronary diseases and 30 due to hypertensive diseases
were treated for more 2 weeks. Patients underwent optimized drug treatment, exercise training,
and counseling and education following the national therapy program. At baseline and at the end
of the program, functional status, exercise capacity, and quality of life were assessed using the
Medical Outcomes Study 36-item Short-Form Health Survey.
Result: Left ventricular ejection fraction and New York Heart Association functional class,
as well as measures of ECG, biochemical parameters improved significantly. Physical
functioning ( p<0.05), general heath ( p<0.05), general physical component score ( p<0.05) and
quality of life improved in sum score (p<0.05) on the questionnaire improved significantly. The
latter was inversely correlated to EF score (r= -0.31; p<0.05).
In patients with chronic heart failure, relatively significant improvements in quality of life
can be achieved within more 2 weeks of intensive treatment /




-
12].


494

-









- 
[3], [8], [10]
- 


-  


tim. [1][6]. 


-

- -36
[9].
S lic x ng kê y hc [5], phn mm SPSS.

III. KT QU NGHIÊN CU

Bng 3.1. Các thông s lâm sàng và cn lâm sàng theo gii

Nam (n=43)


p

98,47±19,14
103,26±16,96
>0,05

51,51±13,10
51,56±13,54
>0,05
HATT (mmHg)
133,60±29,79
130,64±28,70
>0,05
HATTr (mmHg)
73,72±20,24
77,18±17,01
>0,05
HATB (mmHg)
93,58±19,80
94,87±19,03
>0,05

53,26±6,53
49,36±9,95
<0,05
NYHA
2,88±0,59
2,95±0,65
>0,05

EF (%)
40,33±12,36
41,00±14,05
>0,05
LVDd (mm)
59,06±10,91
58,76±11,67
>0,05
QTc (ms)
442,43±35,35
469,46±49,45
<0,01
QRS (ms)
111,23±21,16
108,67±26,31
>0,05

11,70±2,61
11,18±2,69
>0,05
Creatinin (µmol/l)
94,58±14,06
85,54±19,29
<0,05
CRP (mg/l)
5,40±3,40
5,83±3,02
>0,05
CHO (mmol/l)
5,19±1,45

5,08±1,18
>0,05
53,26
469,46±49,45 (85,54±19,29
µmol/l) (p<0,05).
495
3.2. Thuu tr suy tim

Bi 3.1. Thuu tr  du tr
 
 
. 



p

49,61±31,96
56,94±26,33
>0,05

48,89±22,46
60,34±20,88
<0,05

83,59±20,02
89,67±15,08
>0,05

66,10±26,38

72,42±21,24
>0,05

67,78±18,89
73,68±12,95
>0,05

77,57±25,64
82,78±19,91
>0,05

78,26±30,83
83,51±26,99
>0,05

82,49±15,38
88,78±9,21
<0,05

63,01±11,80
74,26±12,27
<0,01

74,71±21,75
80,23±16,10
>0,05

69,14±15,43
76,02±11,20
<0,05

  48,89±22,46 sau 
60,34±20,88 (p <0,05). 82,49±15,38 sau 
88,78±9,2 (p <0,05).           63,01±11,80 sau  
74,26±12 (p<0,01).  69,14±15,43
sau  76,02±11,20 (p <0,05).


 
496
3. 

Nguyên nhân suy tim
p


p

69,67±26,49
40,67±29,85
39,14±30,59
<0,001

45,00±30,37
46,67±18,26
55,17±15,50
>0,05

71,40±20,12
86,30±19,97
92,83±13,27

<0,001

48,53±18,95
70,77±27,89
78,55±22,28
<0,001

56,83±15,89
69,67±19,47
76,55±16,04
<0,001

60,13±24,12
82,13±23,78
90,10±19,30
<0,001

59,07±35,80
82,30±28,65
93,17±13,60
<0,001

72,53±13,40
84,40±16,45
90,34±10,23
<0,001

58,23±14,37
62,60±11,28
68,17±6,58

<0,05

59,60±18,14
78,17±21,99
86,07±16,02
<0,001

60,43±17,28
70,13±14,74
76,76±8,74
<0,001

- b

- 

- 7



-36®
nh giá này
- 
48,5 - 







-
theo N

nh





      
48,5 - 52,5 và




nhân suy tim. Trong n
 là 4,88%.


497
theo SF-

- Có 4 thông s





- 
t



lâm sàng
- 

-  
p<0,05).








1. , Nhà x-184.
2. 

-2010, pp.1-52.
3. 

-213
4. 

5. 
6. Suy tim
7. 
  
, tr. 40 .
8. 

6-
2010-288.
9. Damian Jenkinson Crispin Jenkinson, Sasha Shepperd, Richard Lyte, Sophie Petersen,
(1997), Evaluation of treatment for congestive heart failure in patients aged 60 years and
older using generic measures of health status (SF-36 and COOP charts), Age and Ageing,
26, pp.7-13.
10. Robert Bonow Peter Libby, Douglas Mann, Douglas Zipes (2007), Braunwald's Heart
Disease: A Textbook of Cardiovascular Medicine, 8 ed, Libby.
11. Sherbourne CD Ware JJ (1992), The MOS 36 - Item short - form health survey (SF-36)
Conceptual framwork and item selection, Medical care, (30), pp.473 - 483.
12. Ware J. (2003), SF-36® Health Survey Update, Medical Outcomes Trust.